- Home
- ENX vs ACRV Comparison
ENX vs ACRV Comparison
Compare ENX & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENX
- ACRV
- Stock Information
- Founded
- ENX 2002
- ACRV 2018
- Country
- ENX United States
- ACRV United States
- Employees
- ENX N/A
- ACRV N/A
- Industry
- ENX Finance/Investors Services
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- ENX Finance
- ACRV Health Care
- Exchange
- ENX Nasdaq
- ACRV Nasdaq
- Market Cap
- ENX 173.1M
- ACRV 189.0M
- IPO Year
- ENX N/A
- ACRV 2022
- Fundamental
- Price
- ENX $9.69
- ACRV $5.54
- Analyst Decision
- ENX
- ACRV Strong Buy
- Analyst Count
- ENX 0
- ACRV 6
- Target Price
- ENX N/A
- ACRV $22.40
- AVG Volume (30 Days)
- ENX 25.4K
- ACRV 69.3K
- Earning Date
- ENX 01-01-0001
- ACRV 03-27-2025
- Dividend Yield
- ENX 3.94%
- ACRV N/A
- EPS Growth
- ENX N/A
- ACRV N/A
- EPS
- ENX 0.16
- ACRV N/A
- Revenue
- ENX N/A
- ACRV N/A
- Revenue This Year
- ENX N/A
- ACRV N/A
- Revenue Next Year
- ENX N/A
- ACRV N/A
- P/E Ratio
- ENX $61.00
- ACRV N/A
- Revenue Growth
- ENX N/A
- ACRV N/A
- 52 Week Low
- ENX $7.84
- ACRV $3.83
- 52 Week High
- ENX $10.07
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- ENX 51.97
- ACRV 47.59
- Support Level
- ENX $9.63
- ACRV $5.00
- Resistance Level
- ENX $9.77
- ACRV $6.08
- Average True Range (ATR)
- ENX 0.09
- ACRV 0.64
- MACD
- ENX -0.00
- ACRV 0.01
- Stochastic Oscillator
- ENX 37.04
- ACRV 25.68
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.